Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes

What is it about?

People diagnosed with non-type 1 diabetes before the age of 40 have complex causes and many unmet needs. They often have suboptimal control of risk factors and are at high risk of developing multiple complications and premature death. These young people need complex therapies and experience emotional distress and behavioral challenges. Documenting life course events and providing biogenetic markers help these people understand possible causes underlying their young onset diabetes. This is complemented by targeted and intensified treatment delivered by a specialist-led multidisciplinary team for one year in a center-setting away from busy clinics with two annual reviews by a diabetes on top of usual care. This change in setting, team structure and care processes increased precision of diagnosis and therapies, improved all risk factors, preserve beta-cell function and reduce psychological distress with better physician-patient relationship compared to usual clinic-based care.

Featured Image